We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Cell Lines: Current Challenges in Cell Line Development for Therapeutics

Delve into the evolving role of cell lines in therapeutics, from bioprocessing to new genetic tools addressing stability and quality issues.

Article  
Published: December 12, 2024 
Kerry Taylor-Smith
 speaking with 
James Budge, PhD
 & Paula Meleady, PhD
Scientist handling a pipette over a petri dish in a lab, representing cell line research and experimentation.
Credit: iStock

Advancements in automation, artificial intelligence and high-throughput screening are streamlining the selection and optimization of cell lines, improving efficiency while reducing time and costs. These innovations are not only shaping the future of cell-based therapies but are also crucial for the next generation of complex biologics.


Continue reading this article to explore the latest breakthroughs in cell line development and how emerging technologies are addressing key challenges in biopharmaceutical production.


Sponsored by

Meet the Author
A greyscale headshot of Kerry Taylor-Smith
Kerry Taylor-Smith
Freelance Science Writer
Kerry Taylor-Smith is a science writer who covers everything from climate change and the environment, to health and wellness, to material science, astronomy and space. She has a BSc in Natural Sciences from the University of Bath and over a decade of experience writing for various scientific and consumer publications.
Interviewing
White letters "JB" on a navy background.
James Budge, PhD
Postdoctoral Research Associate
James Budge is a postdoctoral research fellow at the University of Kent. His research focuses on engineering Chinese Hamster Ovary (CHO) cell lines and the development of the processes used to manipulate them for improved production of biotherapeutic materials.
White letters "PM" on a navy background.
Paula Meleady, PhD
Associate Professor
Dr. Paula Meleady is an associate professor in the School of Biotechnology at Dublin City University. Her research focuses on the use of proteomic and mass spectrometry technologies to characterize recombinant mammalian cells to gain insights to improving productivity and quality of biopharmaceuticals.
View this Article for FREE Now!
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
Experiencing issues viewing the form? Click here to access an alternate version
Decoratvive background images
Never miss a story
with the Breaking Science News daily newsletter